{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lupus+Nephritis+-+WHO+Class+IV",
    "query": {
      "condition": "Lupus Nephritis - WHO Class IV"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T19:08:34.105Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05938725",
      "title": "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Lupus Nephritis - World Health Organization (WHO) Class III",
        "Lupus Nephritis - WHO Class IV"
      ],
      "interventions": [
        {
          "name": "KYV-101 anti-CD19 CAR-T cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-04-28",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-06-25T19:08:34.105Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05938725"
    },
    {
      "nct_id": "NCT01926054",
      "title": "ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "SLE Glomerulonephritis Syndrome, WHO Class V"
      ],
      "interventions": [
        {
          "name": "Acthar gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2013-07",
      "completion_date": "2018-02-28",
      "has_results": false,
      "last_update_posted_date": "2018-05-11",
      "last_synced_at": "2026-06-25T19:08:34.105Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926054"
    },
    {
      "nct_id": "NCT01169857",
      "title": "Velcade for Proliferative Lupus Nephritis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Proteinuria",
        "Hematuria"
      ],
      "interventions": [
        {
          "name": "Velcade",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Rogosin Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-08",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2012-04-24",
      "last_synced_at": "2026-06-25T19:08:34.105Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169857"
    },
    {
      "nct_id": "NCT07107659",
      "title": "Safety and Efficacy of ONT01 in Lupus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Lupus Nephritis (LN)",
        "Lupus Nephritis - WHO Class III",
        "Lupus Nephritis - WHO Class IV",
        "Lupus Nephritis - World Health Organization (WHO) Class III",
        "Lupus",
        "SLE",
        "Systemic Lupus Erythematosus",
        "Systemic Lupus Erythematosus (Disorder)"
      ],
      "interventions": [
        {
          "name": "ONT01 is a small molecule CD11b modulator.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2026-09-04",
      "completion_date": "2030-05",
      "has_results": false,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-06-25T19:08:34.105Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07107659"
    },
    {
      "nct_id": "NCT06265220",
      "title": "AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Nephritis - WHO Class III",
        "Lupus Nephritis - WHO Class IV",
        "Refractory Systemic Lupus Erythematosus",
        "SLE"
      ],
      "interventions": [
        {
          "name": "AB-101",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artiva Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2024-04-03",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-06-25T19:08:34.105Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265220"
    }
  ]
}